COMUNICADO: European Commission Grants Lilly's LARTRUVO(TM) (olaratumab), in Combination with Doxorubicin, Approval for the Treatmen

 
Consulta el estado del tiempo
Consulte el estado del Tráfico y del Tiempo para estos días >>
Consulta el estado del tráfico
Contador

COMUNICADO: European Commission Grants Lilly's LARTRUVO(TM) (olaratumab), in Combination with Doxorubicin, Approval for the Treatmen

Publicado 11/11/2016 9:21:32CET

LARTRUVO(TM) is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.

About The Royal Marsden NHS Foundation TrustThe Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.

Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 50,000 NHS and private patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.

Lilly Forward-Looking StatementThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the potential of LARTRUVO (olaratumab) as a treatment of advanced soft tissue sarcoma, and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There can be no guarantee that future study results and patient experience will be consistent with the study findings to date. Among other things, there can also be no guarantee that LARTRUVO will receive regulatory approval for any future indications or that it will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to: Karen Glowacki; kglowacki@lilly.com; 317-370-1177 (media)

Philip L. Johnson; philip_johnson_l@lilly.com;
317-748-1122 (investors)

Logo -- http://photos.prnewswire.com/prnh/20031219/LLYLOGO [http://photos.prnewswire.com/prnh/20031219/LLYLOGO]

Web site: http://www.lilly.com/

Mejora la comunicación de tu empresa con Europa Press Comunicación

Este sitio web utiliza cookies propias y de terceros, puedes ver nuestra política de cookies -
Uso de cookies